Fact CheckerSign in

NCT07129551Recruiting

Navigation, Outcomes and Quality-of-life in Prostate Cancer Patients Undergoing PSMA-targeted Surgery

Source: ClinicalTrials.gov · Last updated 12 Jan 2026

Brief summary (registry, in English)

As part of a feasibility study, it's planned to use a 3D virtual mixed reality model with prostate cancer patients who show signs of lymph node metastasis and are scheduled for surgery. The model is based on PSMA PET imaging performed prior to surgery and will be evaluated by surgeons, the surgical team, and patients as part of the consultation process. First, the researcher investigates whether the removal of lymph node metastases has improved compared to the data in the literature . In addition, the study examines how the 3D model influences the movement of surgical instruments and the efficiency of surgical removal of lymph node metastases. To this end, the analyzed recorded video and position data of the instruments used during procedures performed with a surgical robot. It's also an aim to develop two methods-using landmarks and visual position tracking-for more targeted navigation during surgery. Additionally, short-term results examine, such as PSA response rates, as an indication of successful lymph node metastasis removal and patient quality of life.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
102 (estimated)
First submitted
5 Aug 2025
Start date
21 Jan 2026
Primary completion date
31 Dec 2027
Lead sponsor
Martini-Klinik am UKE GmbH
NCT number
NCT07129551

What you commit to

  • Study type: Interventional
  • Planned participants: 102
  • From 21 Jan 2026 to the primary completion date, 31 Dec 2027
  • 2 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • contraindication for surgical intervention
  • androgen deprivation therapy (ADT) within the last 3 months

Age

  • Estimated life expectancy \<10 years

Who the study is looking for

  • Cohort A:
  • Patients with hormone-sensitive prostate cancer scheduled for radical prostatectomy with pelvic lymph node dissection
  • \<3 PSMA-PET-avid lymph node metastases (PSMA expression score \>2) in the pelvis.
    • Cohort B:
  • Patients with hormone-sensitive recurrent prostate cancer after radical prostatectomy with planned pelvic salvage lymph node dissection
  • \<3 PSMA-PET-avid lymph node metastases (PSMA expression score \>2) in the pelvis
  • PSA value \<2ng/ml.

Age in the registry: 18 years to 78 years · Sex: Male · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (2)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Anke Renter
Coordinator of this site? Confirm its status
HamburgGermanyNot yet recruiting
Martini Klinik
Coordinator of this site? Confirm its status
HamburgGermanyRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.